Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

USPSTF Guidelines for HT in Postmenopausal Women

JAMA; 2017 Dec 12; US Preventive Services Task Force

The US Preventive Services Task Force (USPSTF) has issued a recommendation statement for hormone therapy for the primary prevention of chronic conditions in postmenopausal women. The guideline updates the 2012 USPSTF recommendation and determined after a review of the evidence (18 clinical trials) that although the use of hormone therapy to prevent chronic conditions in postmenopausal women is associated with some benefits, there is also a substantial increase in risk of harms. The updated recommendation statement reads:

  • The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women. (D recommendation)
  • The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy. (D recommendation)

Citation:

US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women. US Preventive Services Task Force recommendation statement. JAMA. 2017;318(22):2224–2233. doi:10.1001/jama.2017.18261.